Showing 2271-2280 of 6774 results for "".
Can You Afford to Opt Out of Medicare?
https://practicaldermatology.com/topics/practice-management/can-you-afford-to-opt-out-of-medicare/23884/What to consider when making the the decision and the steps to take.Assessing the Pediatric Dermatology Workforce
https://practicaldermatology.com/topics/pediatric/assessing-the-pediatric-dermatology-workforce/23834/Physician Spotlight: Steven R. Feldman, MD, PhD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-4/23801/Teledermatology Update
https://practicaldermatology.com/topics/practice-management/teledermatology-update/20146/Many dermatologists and dermatologic surgeons adopted teledermatology or began to use it more frequently throughout the COVID pandemic. Many consultations and post-operative follow-up appointments were handled through telemedicine platforms. Anthony Rossi, MD talks about the benefits of this technolDermWireTV: Sotyktu Approval, Cetaphil at 75, Psoriasis/Depression Link
https://practicaldermatology.com/topics/psoriasis/dermwiretv-sotyktu-approval-cetaphil-at-75-psoriasisdepression-link/20138/FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the oral treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. April Armstrong, MD discusses the first TYK-2 inhibitor approved for psoriasis. As Cetaphil (Galderma)Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-37/23755/New Products
https://practicaldermatology.com/columns/new-products/new-products-4/23753/Applying White Glove Service in the Practice
https://practicaldermatology.com/topics/practice-management/applying-white-glove-service-in-the-practice/23643/Help set your practice apart with these tips for providing unparalleled customer service to your patients.DermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility studyUnintended Consequences: Face Masks and Cosmetic Healing
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/unintended-consequences-face-masks-and-cosmetic-healing-1/23612/Wearing a face covering to reduce risk of COVID-19 may compromise healing from cosmetic surgery. Should lower face procedures be postponed?